Biotech Firm Jumps on FDA Approval, Injects 51% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Bitcoin is booming. ETFs are breaking records.

But the world’s top crypto minds say this is only the beginning.

An exclusive summit just opened access to 27 crypto insiders—including Tether’s co-creator and top fund managers—to share altcoin plays, ETF windfall predictions, and real-time market moves.

This exclusive summit offers rare insight into where the smart money is headed next.

[Get Your Free Ticket to the 2025 Crypto Community Summit]

U.S. equities started the session on the wrong foot but bounced back and closed higher, driven by a tech rally led by Oracle.

Boeing (NYSE: BA) is under renewed pressure after an Air India 787 Dreamliner crashed shortly after takeoff, raising serious safety concerns just as the company was trying to rebuild trust with regulators, airlines, and investors.

Initial reports from Ahmedabad, India, confirm the aircraft went down minutes after departure, resulting in one of the deadliest aviation incidents in a decade.

While the cause remains under investigation, the market reacted quickly, sending Boeing’s stock lower as investors recalibrated their confidence in the company’s recovery narrative.

The timing couldn’t be worse for Boeing, which had recently received growing industry support following production wins in May and renewed delivery confidence from major airline partners.

Now, those gains risk being overshadowed by the emotional and reputational impact of another high-profile tragedy.

For long-term investors, this is a pivotal moment. The 787 had never experienced a fatal crash until now. The Dreamliner line was seen as a cornerstone of Boeing’s next phase of stability.

Any link between this crash and design or quality will reignite concerns from the 737 MAX era, and those scars haven’t fully healed.

Those eyeing an entry point into Boeing should closely watch upcoming findings. If this tragedy is linked to operational oversight, it could stall Boeing’s rebound.

But if ruled unrelated to aircraft fault, short-term panic could present a buying opportunity in a deeply scrutinized but globally essential brand.

With other key suppliers also facing market pressure, investor attention now turns to Boeing’s next move and the transparency of the investigation process.

Trump’s recent crypto announcement just triggered a major market shift—right as Bitcoin and ETFs hit fresh highs.

Institutional money is pouring in, but some of the smartest minds in crypto are looking beyond Bitcoin.

Now, 27 top insiders—co-creators of Tether, Solana, and THORChain—are revealing what comes next.

From hidden altcoin plays to major predictions, this is rare access to crypto’s elite.

[Claim Your Free Ticket to the Crypto Community Summit 2025]

BioNTech (NASDAQ: BNTX) is acquiring German biotech CureVac in an all-stock deal valued at $1.25 billion as it aims to expand its mRNA-based cancer treatment pipeline.

The move unites two companies once considered rivals in the COVID-19 pandemic and signals BioNTech's long-term strategy beyond the pandemic.

This deal grants BioNTech access to CureVac's oncology programs, mRNA technology, and manufacturing capabilities while resolving a lengthy patent dispute between the two.

CureVac shareholders will receive BioNTech stock at a premium, and a key backer, Dietmar Hopp, is already on board.

Investors will view this as a strategic effort to build future revenue streams and expand the company's presence in high-potential therapies.

It also reflects the company's intent to actively defend and expand its intellectual property portfolio while doubling down on cancer research partnerships.

For those not yet in stock, this deal may be a signal to closely watch BioNTech's next steps.

The acquisition adds risk but also unlocks scale, positioning BNTX as a consolidator in the competitive mRNA oncology race.

The transaction awaits regulatory clearance but marks one of the most notable biotech M&A moves of the year so far.

Summer market momentum is here—and these 7 tickers are at the center of it.

This free investor guide features top-ranked stocks selected for their growth potential, market trends, and expert analysis.

It’s a must-read for anyone looking to position their portfolio for a strong second half.

The list is available for FREE, but only for a limited time.

Grab the “Top 7 Stocks for Q2 2025” Now

BlackRock (NYSE: BLK) is setting bold new targets. The world's largest asset manager outlined its vision to raise $400 billion in private market capital by the end of the decade.

The plan, revealed during its Investor Day, also includes a revenue goal of $35 billion annually by 2030, up from $20 billion in 2024.

To get there, BlackRock is placing private credit, infrastructure, and real assets at the heart of its strategy.

This marks a significant shift from traditional indexing and ETF dominance toward alternative investments with higher margins and long-term lock-in from clients like insurers and sovereign wealth funds.

For investors, this strategy signals where BlackRock believes future value lies. Private markets are booming, and so is competition.

Names like Blackstone and KKR dominate the space, but BlackRock is catching up quickly through recent acquisitions, including HPS Investment Partners, Global Infrastructure Partners, and Preqin.

The firm's growing exposure to private credit and infrastructure positions it for long-term fee growth and a stickier client base.

But there are trade-offs. Scaling private markets takes time, integration, and performance execution.

Investors currently in BLK may experience increased volatility as the company rebalances its growth engines.

Still, this shift could future-proof its model in a world where AI, inflation, and geopolitical risk are reshaping capital flows.

New investors may view this as an opportunity to enter the inflection point before private credit and tangible assets become fully mainstream. 

BlackRock's strategic vision is unmistakable: mere dominance in the public markets is insufficient for future success.

UroGen Pharma Ltd [URGN] $11.09 (+51.92%)

UroGen Pharma shares surged after the FDA approved its bladder cancer drug ZUSDURI, marking the first and only treatment for this type of recurrent cancer.

Sagimet Biosciences Inc [SGMT] $8.67 (+40.06%)

Sagimet Biosciences rose as analysts boosted earnings estimates and price targets following strong Phase 3 acne trial results reported by its China-based development partner.

Houston American Energy Corp [HUSA] $7.23 (+32.38%)

Houston American Energy rose to its highest in nearly three months as Middle East tensions pushed oil prices, prompting speculative buying in small-cap energy stocks.

Simulations Plus Inc [SLP] $20.01 (-24.32%)

Simulations Plus dropped after cutting its full-year revenue forecast, citing project delays and reduced budgets among pharma clients.

Gamestop Corp [GME] $21.80 (-23.64%)

GameStop stock plunged after announcing a $1.75 billion convertible note offering, sparking fears of share dilution and uncertainty over how the capital will be used.

Karooooo Ltd [KARO] $47.50 (-20.21%)

Karooooo declined after its CEO priced a $75 million secondary offering at a steep discount, raising concerns over insider selling.

ETFs are flooding crypto markets with institutional capital, and a new wave of opportunity is just beginning.

While most are focused on Bitcoin, 27 of the most trusted crypto insiders are tracking where the smart money is really going.

Their findings will be revealed during the Crypto Community Summit 2025, and access is currently free.

Expect key predictions, altcoin picks, and the next phase of growth few are prepared for.

[Claim Your Free Summit Pass Now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.